Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation
Masaaki Yoshikawa(Japan Aerospace Exploration Agency), Haruki Koike(Shinshu University), Kohei Suzuyama(Saga University), Chika Shichijo(Saga University), Yuki Hoshino(Nagano Matsushiro General Hospital), Toshihiro Ide(Saga University), Hiroshi Takashima(Kagoshima University), Keisuke Tsumura(Saga University), Koya Tanaka(Saga-Ken Medical Centre Koseikan), Motohiro Yukitake(Shirasagi Hospital), Yukako Inoue(Saga-Ken Medical Centre Koseikan), Makoto Eriguchi(Saga University)
Cited by 13
Related Papers
Characterizing and navigating small bodies with imaging data
|Meteoritics and Planetary Science|2008|269
Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy
|Neurology|2004|224
Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status
|Neurology|2001|153
Periaxin mutations cause a broad spectrum of demyelinating neuropathies
|Annals of Neurology|2002|115
Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population
|Journal of Neurology Neurosurgery & Psychiatry|2008|114